載入中
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
最新資料
¥761
−¥5.00 · -0.65%
盤中時間採用JST。市場資料可能有所延遲。
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
日內區間
目前¥761
52週區間
目前¥761
盤中時間採用JST。市場資料可能有所延遲。
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
日內區間
目前¥761
52週區間
目前¥761
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
